Akeso’s Ivonescimab Beats Durvalumab Standard in Phase 3 Biliary Tract Cancer Trial
Akeso’s PD-1/VEGF bispecific antibody ivonescimab has delivered another major Phase 3 victory, this time outside lung cancer, demonstrating a statistically significant overall survival advantage over durvalumab plus chemotherapy in first-line advanced…
Bio-Thera and Avalon Pharma Sign MENA Deal for BAT2406, Proposed Dupixent Biosimilar
China’s Bio-Thera Solutions and Saudi Arabia-based Avalon Pharma have entered into commercialization and license agreements for BAT2406, a proposed biosimilar to Dupixent® (dupilumab), covering Saudi Arabia and the broader Middle East and North Africa…
iRegene secures another 260 million yuan in Series C+ financing to accelerate pipeline development
On July 2nd, iRegene Therapeutics announced the completion of a RMB 260 million Series C+ financing round. This round was led by Chengdu Science and Technology Venture Capital, with participation from CITIC Securities Capital, Xichuan Venture Capital,…
BeiGene and Revolution Medicines Enter Strategic Collaboration
On August 10, BeiGene announced a multi-faceted collaboration agreement with Revolution Medicines. Under the agreement, the two companies will collaborate on clinical trials to jointly evaluate combination therapies of some of BeiGene’s…
Xgene secured RMB 250 million in series D financing to develop novel non-opioid analgesic drugs
Recently, Xgene Pharmaceutical Inc. (“Xgene”), a company focusing on the research and development of innovative drugs in the fields of pain and neurology, completed a RMB 250 million Series D financing round. This round was jointly led by Yifeng…
XellSmart’s universal cell therapy drug for Parkinson’s disease receives Fast Track designation from the US FDA
On July 28, 2026, XellSmart Bio‘s independently developed allogeneic universal “off-the-shelf” XS411 cell therapy injection, for the treatment of Parkinson’s disease, the world’s second most prevalent neurodegenerative…